Items where authors include "van der Meer, R."

Article

Keating, C., Yonker, L.M., Vermeulen, F. et al. (320 more authors) (2025) Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine, 13 (3). pp. 256-271. ISSN 2213-2600

Uluer, A.Z., MacGregor, G., Azevedo, P. et al. (103 more authors) (2023) Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. The Lancet Respiratory Medicine, 11 (6). pp. 550-562. ISSN 2213-2600

Flume, P.A., Biner, R.F., Downey, D.G. et al. (190 more authors) (2021) Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. The Lancet Respiratory Medicine, 9 (7). pp. 733-746. ISSN 2213-2600